For example, chemokine receptor-modified T-cells (e.g., CCR4- and CCR6-engineered variants) selectively home to tumor-draining lymph nodes and intratumoral regions in murine colon cancer models, markedly improving therapeutic efficacy (27). Here, CCR6 is linked to neoplasm.